Status:
COMPLETED
Dose-Escalation Safety and Pharmacokinetic Study of ATX-101
Lead Sponsor:
Kythera Biopharmaceuticals
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101
Detailed Description
This is a single center, open-label, dose-escalation study in which subjects will receive 4 different dosage concentrations (3 dosing paradigms) of ATX-101 in a single dosing session.
Eligibility Criteria
Inclusion
- Healthy males or nonpregnant females
- Age 18 to 65
- Sufficient submental fat for injections
- Signed informed consent
Exclusion
- Prior interventions in the chin or neck area
- History or presence of drug or alcohol abuse
- Treatment with an investigational agent within 30 days before the dose
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00618709
Start Date
January 1 2008
End Date
January 1 2009
Last Update
May 30 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MDS Pharma Services
Tempe, Arizona, United States, 85283